Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma, Inc. (NASDAQ:TBPH) in a research report report published on Wednesday, July 19th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other research analysts have also commented on TBPH. Piper Jaffray Companies reiterated an overweight rating and set a $42.00 price target on shares of Theravance Biopharma in a report on Wednesday, March 22nd. Needham & Company LLC lifted their price target on Theravance Biopharma from $40.00 to $45.00 and gave the stock a buy rating in a report on Thursday, May 11th. Leerink Swann set a $47.00 price target on Theravance Biopharma and gave the stock a buy rating in a report on Wednesday, May 10th. ValuEngine upgraded Theravance Biopharma from a sell rating to a hold rating in a report on Friday, June 2nd. Finally, BidaskClub upgraded shares of Theravance Biopharma from a hold rating to a buy rating in a report on Saturday, June 24th. Four investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Theravance Biopharma has a consensus rating of Hold and a consensus target price of $41.13.
Shares of Theravance Biopharma (NASDAQ:TBPH) traded down 2.00% during midday trading on Wednesday, hitting $32.81. 142,719 shares of the stock traded hands. The company’s 50 day moving average price is $38.72 and its 200-day moving average price is $35.69. Theravance Biopharma has a 12-month low of $23.80 and a 12-month high of $43.44. The stock’s market cap is $1.75 billion.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.14) by $0.13. Theravance Biopharma had a negative return on equity of 67.69% and a negative net margin of 641.67%. The company had revenue of $3.09 million for the quarter, compared to analysts’ expectations of $5.07 million. On average, equities research analysts expect that Theravance Biopharma will post ($4.61) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Theravance Biopharma, Inc. (TBPH) a $55.00 Price Target” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/07/29/cantor-fitzgerald-analysts-give-theravance-biopharma-inc-tbph-a-55-00-price-target-updated.html.
A number of hedge funds have recently modified their holdings of TBPH. Woodford Investment Management Ltd raised its stake in shares of Theravance Biopharma by 1.9% in the first quarter. Woodford Investment Management Ltd now owns 10,705,108 shares of the biopharmaceutical company’s stock valued at $393,948,000 after buying an additional 197,500 shares during the period. BlackRock Inc. raised its stake in shares of Theravance Biopharma by 117,412.4% in the first quarter. BlackRock Inc. now owns 3,512,445 shares of the biopharmaceutical company’s stock worth $129,326,000 after buying an additional 3,509,456 shares during the period. Vanguard Group Inc. raised its stake in shares of Theravance Biopharma by 4.2% in the first quarter. Vanguard Group Inc. now owns 3,080,296 shares of the biopharmaceutical company’s stock worth $113,417,000 after buying an additional 125,223 shares during the period. State Street Corp raised its stake in shares of Theravance Biopharma by 2.3% in the first quarter. State Street Corp now owns 870,254 shares of the biopharmaceutical company’s stock worth $32,042,000 after buying an additional 19,230 shares during the period. Finally, Norges Bank acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth about $27,631,000. Hedge funds and other institutional investors own 84.30% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
